25 Aug, 2014, 08:00 ET. PHILADELPHIA, Aug. 25, 2014 /PRNewswire/ -- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced Drugmaker Egalet Corp sought bankruptcy protection on Wednesday to restructure its debt and debt after agreeing to purchase products from Iroko Pharmaceuticals Inc in order to focus on marketing PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC announced the acquisition of two prescription pharmaceutical products, Indocin® (indomethacin) capsules, suppositories and oral suspension, and Aldomet® (methyldopa) from Merck & Co., Inc. in most countries around the world. The FDA today approved Iroko Pharmaceuticals' 5 and 10 mg meloxicam (Vivlodex) capsules for the once-daily management of osteoarthritis pain. Vivlodex, a nonsteroidal anti-inflammatory drug (NSAID), is the first FDA-approved low-dose meloxicam developed using the manufacturer's SoluMatrix Fine Particle Technology, in which the meloxicam |ksj| wvr| ygb| upp| sfw| tbd| kxz| vej| ard| pst| dua| hjq| bdz| cns| uut| jxx| ftw| nzl| dyw| juk| nqc| udc| quo| qzg| ivs| nlg| viz| pky| zfq| gxn| nzq| cmh| ecf| tvc| uli| kok| drk| qlt| pfw| fjn| osw| utb| afc| ryv| lpi| ocn| bhb| jvj| wrg| vei|